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ABSTRACT Several biophysical techniques have been used to determine differences in the aggregation proﬁle (i.e., the
secondary structure, aggregation propensity, dynamics, and morphology of amyloid structures) and the effects on cell viability
of three variants of the amyloid b peptide involved in Alzheimer’s disease. We focused our study on the Glu22 residue, comparing
the effects of freshly prepared samples and samples aged for at least 20 days. In the aged samples, a high propensity for aggre-
gation and b-sheet secondary structure appears when residue 22 is capable of establishing polar (Glu22 in wild-type) or hydro-
phobic (Val22 in E22V) interactions. The Arctic variant (E22G) presents a mixture of mostly disordered and a-helix structures (with
low b-sheet contribution). Analysis of transmission electron micrographs and atomic force microscopy images of the peptide
variants after aging showed signiﬁcant quantitative and qualitative differences in the morphology of the formed aggregates.
The effect on human neuroblastoma cells of these Ab12–28 variants does not correlate with the amount of b-sheet of the aggre-
gates. In samples allowed to age, the native sequence was found to have an insigniﬁcant effect on cell viability, whereas the
Arctic variant (E22G), the E22V variant, and the slightly-aggregating control (F19G-F20G) had more prominent effects.INTRODUCTION
Aggregation processes are related to the misfolding of
proteins and subsequent onset of diseases such as AD,
transmissible spongiform encephalopathy, and type II dia-
betes (1). In the case of AD, the disease is associated
with the deposition in the brain of fibrils with a characteristic
b-sheet structure. However, it was recently postulated that
neurotoxicity is more dependent on the presence of oligo-
meric species (2). The major components of these fibrils
and oligomers are the 40- and 42-residue amyloid
b peptides. The K17LVFFA21 region (hydrophobic central
core) of these peptides has been shown to be important
for aggregation, but other regions contribute as well, since
several smaller nonoverlapping fragments form fibrils
in vitro. Fibrillization, which is a nucleation-dependent
process, involves a wide variety of aggregated species
ranging from dimers to large fibrils. The overall picture of
the ensemble of structures and the kinetics of their reactions
on a timescale of weeks will be called the ‘‘aggregation
profile’’ in this work.
As in sporadic AD, FAD, an inherited form of AD,
promotes neurotoxic effects through different intermediate
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0006-3495/09/07/0277/9 $2.00species, such as protofibrils. Most of the variants related to
FAD, such as the Dutch (E22Q), Italian (E22K), and Arctic
(E22G) variants, are found in position 22 of the Ab peptide.
The Arctic variant is characterized by an early onset of the
disease, and the protofibrils have been suggested as the
neurotoxic agent in this FAD (3,4).
Since residue 22 is a determinant for FAD, we analyzed the
role of residue 22 in the aggregation and toxicity of the Ab
peptide using a short Ab fragment, Ab12–28, and variants
thereof (see Table 1 for peptide sequences). We chose this
fragment because 1), it includes the central hydrophobic
core (residues 17–21); 2), it enables electrostatic and salt
bridge interactions involving some of its charged residues
(His13, His14, Lys16, Glu22, Asp23, and Lys28) (5,6); 3), it
forms fibrils (7); and 4), it may clarify conflicting results
obtained with Ab1–40 and Ab1–42 in studies focusing on
variants at position 22 (8–11). Here we focus on the local
effects of the variants using a shorter version of the peptide,
in accordance with other recent studies with shorter fragments
(12,13).
In this study we used several biophysical methods to inves-
tigate the consequences of amino acid exchange at position 22
by comparing the Ab12–28 peptide native sequence with the
Arctic variant (E22G) and a variant not found in FAD patients
(E22V). In the variants, the acidic residue 22 of the native
sequence is replaced by either the smallest side-chain Gly,
which should increase the backbone flexibility, or by a hydro-
phobic side chain of Val, which is not able to undergo polar
interactions. As a less-aggregating control, we also included
the double variant F19G-F20G (GG) (14). To characterize
the differences in secondary structure as a function of the
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Pera´lvarez-Marı´n et al.amino acid at position 22,we usedCDandFTIR spectroscopy
methods. ACongo red binding assay, AFM images, and TEM
micrographs were used to quantify amyloid/fibrillar aggre-
gates and their morphology. SDSL-EPR was used to deter-
mine the aggregation dynamics of the different variants. To
correlate the biophysical and aggregation profile of the
peptides with their toxicity, we also assayed cell viability
for the different variants.
MATERIALS AND METHODS
Sample preparation
Peptides of immunograde purity were purchased from NeoSystem Labora-
toire (Strasbourg, France). Fresh samples of the different Ab12–28 variants
were prepared using the protocol described in Jarvet et al. (15). The final
concentrations were 0.04 mM or 1 mM in 10 mM sodium phosphate buffer
at pH 7.25. The samples were aged by keeping 1 mM of the freshly prepared
samples at room temperature for 20–25 days.
CD spectroscopy
Thermal unfolding experiments on fresh samples at 0.04 mM (kept in ice
before the starting of the experiment) were acquired in a JASCO 720 spec-
trometer (JASCO, Easton, MD) with cuvettes of 2 mm pathlength. The
temperature was kept stable for 8 min at each temperature step with
a PTC-343 temperature controller. The resulting spectra are the average of
10 scans collected at a 100 nm/min scan rate and a detector response time
of 2 s at each temperature. Buffer subtraction was used for baseline correc-
TABLE 1 Ab12–28 peptide sequences used in this study
Peptide variant Nomenclature
VHHQKLVFFAEDVGSNK WT*
VHHQKLVFFAGDVGSNK E22G
VHHQKLVFFAVDVGSNK E22V
VHHQKLVGGAEDVGSNK GG
E11C-MTSSLy
F20C-MTSSL
*Underlined residues indicate the different substitutions.
yThe dot in the chemical structure indicates the nitroxide radical.
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detachable cuvette was used.
FTIR spectroscopy
FTIR spectroscopy was performed with a Bruker IFS66 spectrometer
(Bruker, Ettlingen, Germany) at a resolution of 2 cm1. A total of 1000
scans were collected. Then 1 mM of each peptide sample in 2H2O was
placed between two BaF2 windows with a 30 mm well and the sample
was thermostated at 293 K for 30 min before measurements were obtained.
Buffer subtraction was performed until the band at 1460 cm1 (HOD
exchange) was almost absent. Sample preparation and aging were carried
out as described above but using deuterated reagents.
Electron microscopy
For electron microscopy, 10 mL of the aged samples were placed onto copper
grids coated with formvar and carbon, and adsorption of the aggregates was
allowed for 10 min. Excess solvent was removed and the grids were washed
twice with double-distilled water to remove salts. Staining of the aggregates
with a 3% uranyl acetate solution was carried out for 1 min. Another double-
distilled water wash was performed and excess of solvent was removed with
Whatman paper (Whatman, Kent, UK). The grids were allowed to dry before
micrographs were acquired in a Tecnai 12 BT (FEI, Hillsboro, OR) micro-
scope with a Gatan US 1000 P camera (Gatan, Pleasanton, CA).
AFM
AFMmeasurements were performed on a PICO PLUS microscope (Agilent,
Santa Clara, CA) under tapping mode using a 100 mm scanner with acous-
tically driven cantilevers operating at a resonance frequency in the 5–10 kHz
range. The scanning resolution was 512  512 pixels. The scanning was
performed in trace and retrace to avoid scan artifacts. For ambient imaging,
the aged samples of the different variants were diluted 100-fold in MilliQ
water (Millipore, Billerica, MA). After 5 min incubation on freshly cleaved
mica, the samples were subsequently washed three times with 200 mLMilliQ
water and dried overnight at room temperature. The dimensions of the
amyloid structures were analyzed by AFM cross-section analysis.
EPR spectroscopy
Ab11–28 E11C and Ab12–28 F20C peptides (with a Cys placed in position 11
or 20, respectively) were purchased from NeoSystem Laboratoire (Stras-
bourg, France). Spin labeling of these Cys-substituted peptides with MTSSL
was carried out as previously described (16). A concentration of 0.01 mM of
spin-labeled peptide (E11C-MTSSL or F20C-MTSSL) was mixed with
0.99 mM of each of the unlabeled peptides and kept under aging conditions.
A control with only 0.01 mM of the spin-labeled peptide was kept under
aging conditions. The spectra did not show any line-broadening or signifi-
cant intensity loss, indicating the absence of aggregates under these condi-
tions.
Continuous-wave EPR spectra were recorded on a Bruker Lexus500 spec-
trometer (Bruker, Ettlingen, Germany) at 9.8 GHz, and 50 mL of each
sample were placed in a 1 mm glass capillary. An average of 25 scans
were obtained at a modulation frequency of 100 kHz with 1 G of modulation
amplitude over a 100 G scan width. Measurements were carried out at room
temperature.
Congo red binding assay
To determine the level of aggregation by Congo red absorption, we used
a modified variant of the protocol described in Klunk et al. (17). Aliquots
of the peptide sample (final concentration 0.04 mM) were mixed with Congo
red (final concentration of 0.003 mM). The absorbance at 400 and 540 nm
was recorded in a JASCO V-560 UV/Vis spectrophotometer (JASCO,
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mined by the following formula:
½Congo red þ Aß ¼ ðA540=47800Þ  ðA400=68300Þ
 ð½Congo red=4:77 :Þ
The values obtained were zeroed for the value of Congo red without peptide
sample, yielding the ratio shown below in Fig. 5.
MTT cell viability assay
Cell viability was examined by means of the MTT assay, which depends on
the reduction of the tetrazolium salt MTT to formazan by living cells.
Human SH-SY5Y neuroblastoma cells were cultured in 24-well plates and
treated overnight with 0.01 mM of the different Ab fragments (both aged
and freshly prepared). After treatment, an MTT solution (0.3 mg/mL)
made in serum-free modified Eagle’s medium without phenol red was
then added to the cells. After 1 h of incubation at 37C, the MTT solution
was aspirated and DMSO was added to the cells. Aliquots were transferred
to a 96-well plate and absorbances were measured at 540 nm in a plate reader
(Safire II-Basic; Tecan Austria GmbH, Gro¨dig, Austria). Results were
expressed as percentages of the respective value obtained for cells treated
with 10 mM sodium phosphate buffer at pH 7.25.
RESULTS
We compared the aggregation profile of different variants
of the Ab12–28 peptide with substitutions at position 22
(Table 1) from the starting point to the formation of fibrils.
For that purpose, a comparison of the properties of fresh
samples and aged samples (kept at room temperature for
20–25 days) was carried out.
Secondary structure
The thermal stability of the secondary structure of the mono-
mers (freshly prepared sample at 0.04 mM) of the different
variants was monitored by CD (Fig. 1). A temperature
ramp from 0 to 60C was performed, and the irreversibility
of the secondary structure transitions was evaluated by reac-
quiring the spectrum at 0C after the thermal ramp. For one
of the peptides (E22V), it was possible to determine the
midpoint of the transition by fitting the data to a sigmoid
function.
For the Ab12–28 WT, a statistical distribution of structures
(negative intense minimum at 195 nm) with a considerable
ppII helix contribution (positive shoulder at ~220 nm) was
detected (Fig. 1) (18). As the temperature increased, the posi-
tive shoulder decreased, indicating less ppII helix at higher
temperatures. This structural transition was reversible. The
variant GG showed less ppII helix contribution at low temper-
ature, and a further decrease was detected at ~222 nm (revers-
ible transition) as the temperature increased. The Ab12–28
fragment containing the arctic E22G variant gave CD spectra
similar to those obtained for the WT (Fig. 1), and showed
a reversible thermal transition corresponding to ppII helix
loss. The Ab12–28 fragment with the E22V variant showed
the most striking behavior, with a typical b-sheet spectrum
for the fresh sample at 0.04 mM (19), and a maximum at202 nm and a minimum at 227 nm (Fig. 1). Heating led to
an irreversible transition with a midpoint at 40C, which
was accompanied by a loss of the CD signal indicative of
the formation of large, light-scattering aggregates.
FIGURE 1 Thermal unfolding of Ab12–28 variants. Thermal ramps were
performed from 0 (thick black line) to 60C (thick gray line). CD spectra
were acquired each 10C (20, 30, 40, 50C; thin gray lines). The revers-
ibility was checked by acquiring a 0C spectrum (represented by  symbol)
after the thermal ramp. For E22V, the inset plot shows the evolution of the
mean residual molar ellipticity at the specified wavelength. The midpoint
of the transition (40C) is indicated corresponding to the inflection point of
sigmoid equation fit. All peptide samples (0.04 mM) were in 10 mM phos-
phate buffer at pH 7.25 and kept in ice before starting the experiment.Biophysical Journal 97(1) 277–285
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state of the different peptides (1 mM of peptide aged for at
least 20 days) by FTIR spectroscopy. This technique is
less sensitive than CD to scattering effects induced by aggre-
gation, and has been widely used to assess the secondary
structure of proteins (20). The most commonly used band
is the amide I band, which is sensitive to hydrogen bonding
and secondary structure. To avoid overlap by water absorp-
tion in this region, we performed the analysis of the amide I0
band after deuteration of the peptide and subsequent aging of
the sample for 20 days.
Fig. 2 shows the secondary structure of the aggregated/high
concentration state for the different peptides. For secondary
structure assignment, we used the wavenumber intervals
defined in Byler and Susi (21). WT showed a typical antipar-
allel b-sheet spectrum indicated by a low wavenumber band
with high intensity (1616 cm1) and a high wavenumber
band ~10 times less intense (1685 cm1). The control sample
(GG) at 1 mM exhibited a spectrum with a broad and low-
intensity band centered at 1643 cm1 that did not indicate
a preference for a particular type of secondary structure.
FIGURE 2 FTIR spectra of aged peptide samples; 1 mM of peptide in
10 mM deuterated phosphate buffer at pH 7.25 incubated for 20 days at
room temperature. The amide I0 region for the different peptides is plotted.
All the spectra are shown in their original scale, upshifted in the ordinate
scale for a clearer presentation.
Biophysical Journal 97(1) 277–285The Arctic variant E22G showed a broad spectrum centered
at 1660–1645 cm1, which is characteristic of the presence
of helical structures and sampling of a broad range of F and
J angles. There was also some b-sheet contribution indicated
by a shoulder at 1619 cm1. The E22V spectrum showed
a b-sheet structure similar to that of WT, with the presence
of the 1616 and 1685 cm1 bands.
Using FTIR spectroscopy, we were able to discriminate
between the different kinds of aggregates originating from
the different peptide sequences. CD spectroscopy could not
discriminate between the different secondary structures of
samples with high concentration; instead, a loss of the CD
signal was evident, probably due to light-scattering effects
(data not shown). A similar loss of CD signal was observed
for the freshE22Vpeptidewith increased temperature (Fig. 1).
Amyloid morphology
To assess the morphology of the aggregates obtained with
the different peptides, we used TEM (Fig. 3) and AFM
(Fig. 4). In the TEM images, the aged WT, E22G, and
E22V peptides presented observable aggregates (Fig. 3, a,
c, and d), in contrast to the GG peptide (Fig. 3 b). The WT
peptide (Fig. 3 a) had the known typical fibrillar morphology
(7), with a fibril diameter of ~5–10 nm. These fibrils were
seldom stacked. E22G (Fig. 3 c) showed the same fibril
diameter, but these fibrils were arranged in a network-like
fashion. Also for E22V (Fig. 3 d) the diameter was between
5 and 10 nm, but the fibrils were highly stacked, indicating
a higher degree of packing of these fibrils.
AFM analysis provided detail information on the amyloid
structures of Ab peptides. In the AFM analysis shown in
Fig. 4, WT formed mature fibrils and other aggregates
(Fig. 4 a), which were characterized by a wide distribution
of widths measured at a half-height (corresponding to the
diameter of the analyzed cross sections). The widths ranged
from 20 to 100 nm and the heights varied from ~1.5 to
3.5 nm. The minimal height detected for WT short filaments
was ~0.5 nm. It is noteworthy that this is below the commonly
accepted height for a single amyloid protofilament (~2 nm as
shown in previous studies (22,23)). This indicates that the
initial amyloid filaments for Ab12–28 were significantly
thinner than amyloid structures of proteins and polypeptides
of larger molecular weight. The longer fibrils were character-
ized by larger height, which further increased during the
lateral assembly and intertwisting of constituting protofila-
ments. We observed a proportional increase in the periodicity
of twisting with increasing width of the fibrils, which may
reflect the larger number of filaments involved in the fibril
formation. Of interest, ribbon-like assemblies appeared with
a width distribution of 40–80 nm and a height distribution
of 2.0–2.5 nm (Fig. 4 a, inset), indicating the presence of an
additional pathway of fibrillar lateral assembly. Individual
oligomers with a height of ~1.45 nm and width of ~23.5 nm
were also observed, but in significantly smaller amounts.
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fragments. The scale bar equals 100 nm except where
indicated. Insets show micrographs with different length
scales. (a) WT aggregates; the inset scale bar corresponds
to 500 nm. (b) GG peptide; no aggregates were observed.
(c) E22G aggregates; the inset scale bar equals 2000 nm.
(d) E22V aggregates; the inset scale bar equals 500 nm.Large aggregates were absent in the GG peptide sample
(Fig. 4 b). Round-shaped assemblies characterized by
a very wide distribution of heights (data not shown) were
observed. None of them translated into filamentous species
even after very prolonged incubation, indicating that these
multimeric complexes were most likely the end-product of
peptide self-assembly.Probably, the rounded-shapedoligomersare simply formed by the fusing of even smaller oligomeric
species present in solution.
The E22G variant formed very rigid and straight rod-
shaped structures with heights from 2 to 4 nm, which corre-
spond most likely to individual protofilaments (Fig. 4 c).
These structures displayed the tendency to associate laterally
together into thicker assemblies with 20–60 nm of width.FIGURE 4 AFM images of the
different Ab12–28 fragments. The scale
bar equals 200 nm. The inset scale bar
corresponds to 50 nm. (a) WT aggre-
gates. (b) GG peptide. Note the oligo-
meric forms. (c) E22G aggregates. (d)
E22V aggregates. The height and width
distribution of the different aggregates
is plotted for all the variants except for
GG.
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or interwind, meaning that they are more likely to be formed
by lateral accumulations. This is consistent with the wide
distribution of the fibrillar width compared with the rela-
tively narrow distribution in their heights (Fig. 4).
The most massive amyloid structures were observed in the
sample of E22V peptide (Fig. 4 d). In the extensive network
we detected some individual filamentous structures of ~1 nm
in height, but mostly thick fibrillar bundles. In contrast to
the WT peptide amyloids, only relatively short fibrillar
aggregates (not exceeding 400 nm in length) were observed
on the mica surface. Compared with the amyloid aggregates
of E22G peptide, the fibrils of E22V peptide were character-
ized by significant flexibility reflected in the interwinding
of individual protofilaments and in their overall bending.
The periodicity along the fibril axis displayed a dependence
on width similar to that of the WT peptide amyloid (Fig. 4 a).
Some round-shaped oligomeric structures were also present
in the sample with ~1 nm in height and ~16.5 nm in diameter.
Amyloid dynamics
SDSL-EPR has been used previously to determine the
arrangement of amyloid fibrils (24). Inter- and intramolecular
distances have been calculated and accurate models of aggre-
gates have been suggested. In this study, we present an
SDSL-EPR approach to compare the aggregation behavior
of different peptides.
A spin-labeled probe was present during the aggregation
process. The probe consisted of an Ab11–28 native sequence
with an E11C substitution or an Ab12–28 native sequence
with a F20C substitution. Thus, after MTSSL labeling, the
spin label was located either in the N-terminus (E11C-
MTSSL) or in the middle of the Ab peptide (F20C-MTSSL),
yielding two kinds of probe (Table 1). Line-broadening, indi-
cating restriction of movement of a spin label, should be
affected by the relative position of the spin label in the
peptide and by the aggregation profile of the peptide.
To minimize any sample preparation artifacts due to
labeled peptide, the molar ratio of the probe (spin-labeled
peptide) to the nonlabeled peptide was kept at 1:100. The
different peptides were incubated for at least 20 days in the
presence of either one probe or the other. CD spectra at
0.01 mM of these labeled peptides did not show any signifi-
cant secondary structure changes compared with the WT
Ab12–28 (data not shown). After the incubation, EPR spectra
were recorded (Fig. 5). Isotropic rapid tumbling of the spin
label is represented by narrow spectral lines. The slower
dynamics of the spin label gives rise to broader lines. The
GG sample with both probes shows the sharpest EPR lines
(comparable to 0.01 mM of spin-labeled peptide alone; not
shown), indicating rapid tumbling (Fig. 5, c and d).
The WT peptide gave rise to an EPR spectrum composed
of a rapid component and an immobilized component, as
indicated by the appearance of shoulders in the H0 line in
Biophysical Journal 97(1) 277–285the presence of both probes (Fig. 5, a and b). Similarly, the
N-terminal probe in the presence of the E22G variant showed
at least two components indicating immobilization of some of
the spin labels. In the presence of the F20C-MTSSL probe,
E22G showed mainly a rapid component (Fig. 5 f). The
most striking case was E22V, which showed strong immobi-
lization of the spin label in both cases in which the F20C-
MTSSL probe showed the most reduced mobility (Fig. 5, g
and h). This result is in agreement with the tight packing of
the E22V fibrils shown by TEM and AFM.
For all variants except GG, the spectra cannot be explained
by single species, indicating a mixture of both rapidly and
slowly tumbling species (Fig. 5). This mixture of at least two
mobility patterns (slow and fast regimes) was more evident
when the labelwas placed at theN-terminus (Fig. 5, left panel).
The observed EPR signals suggest that the degree of incorpo-
ration of spin-labeled peptide into tightly packed aggregates
varies between the peptide variants and may depend on the
properties of the formed aggregates. A high degree of
FIGURE 5 SDSL-EPR of aged Ab12–28 peptide samples. The different
monomeric peptide samples were incubated in 10 mM phosphate buffer at
pH 7.25, allowing aggregation for 20 days in the presence of E11C or
F20C labeled with MTSSL. The unlabeled peptide being investigated is indi-
cated on the left. The labeled peptide is indicated by a cartoon representation
with a circle showing the relative position of the label. The ratio (mM/mM)
of unlabeled to labeled peptide was 0.99:0.01, giving a final peptide concen-
tration of 1 mM. The spectral features of the nitroxide spin label are indicated
by the H1, H0, and H1 triplet. The spectra for the different mixtures are
plotted in the following order: (a) WT þ E11C-MTSSL, (b) WT þ F20C-
MTSSL, (c) GG þ E11C-MTSSL, (d) GG þ F20C-MTSSL, (e) E22G þ
E11C-MTSSL, (f) E22G þ F20C-MTSSL, (g) E22V þ E11C-MTSSL,
and (h) E22V þ F20C-MTSSL. Dashed lines are visual guides to help the
reader.
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to an EPR spectrum characteristic of an immobilized spin
label, and a low degree of incorporation should result in
a spectrum dominated by rapidly tumbling spin-labeled
peptides free in solution. The EPR spectra, therefore, should
depend on both the concentrations of the various aggregated
species present and the ‘‘tolerance’’ of the aggregates for
the spin-labeled peptide. Accordingly, they should also reflect
the three-dimensional structure of the aggregates. From this, it
is evident that the three-dimensional structures of the WT
aggregates are quite different from those of the E22V variant,
although the secondary structure and the amount of aggre-
gates (see the section below) are very similar.
Amyloid quantiﬁcation
To assess the concentration of the aggregates for the different
Ab12–28 peptide variants, the Congo red binding assay was
used (17). This assay was previously used to quantify the
fibrillar amyloid state of various peptides (25,26). Fig. 6 a
indicates the amount of aggregates reached by the different
variants under aging conditions (1 mM of peptide incubated
for 20 days at room temperature). E22V and WT reached
the highest level of aggregation, followed by E22G (almost
twofold less aggregation than WT). The GG control showed
some Congo red binding, indicating the presence of aggre-
gates in aged samples. Steady-state Thioflavin T fluorescence
measurements were also conducted with the same samples,
showing the same trend (data not shown).
Cell viability
Weanalyzed the effects of the different peptide variants on the
viability of SH-SY5Y neuroblastoma cells. The treatment
with 0.01 mM of freshly prepared peptide samples did not
show any effect, and the treatment with aged WT peptide
also had no effect on cell viability. However, treatment with
0.01 mM of aged samples containing GG, E22G, and E22V
decreased cell viability to 86%, 79%, and 70%, respectively
(Fig. 6 b). GG is the most surprising case, because any level
of toxicity in this slightly aggregating variant is unexpected.
For a direct comparison, more-toxic peptides, such as Ab1–42
and Ab25–35 at 0.01 mM, have been reported to decrease theviability of human neuroblastoma cells to 32% and 51%,
respectively (27).
DISCUSSION
In this study we biophysically characterized the secondary
structure, thermal transition, amyloid content, aggregate
morphology (i.e., the aggregation profile), dynamics, and
toxicity of different variants of the Ab12–28 fragment to deter-
mine the relevance for aggregation and toxicity of residue 22
of the Ab peptide. The nature of this residue has been shown
to be linked to certain forms of FAD, which suggests that it is
crucial for the aggregation profile of the peptide. The results
presented here give stronger support for that concept.
The Arctic variant (E22G) has been described in patients
showing early onset of AD and a protofibril-mediated neuro-
toxic mechanism (28,29). E22V is a variant that has not
been described in patients. However, this variant involves a
single nucleotide substitution in the codon for position 22,
indicating some probability to occur. We also characterized
a slightly aggregating variant (GG) (14), mainly as a control,
which in structural terms behaved as expected. The outcomes
of this study are summarized in Table 2.
E22V showed a b-sheet secondary structure (in both
freshly prepared and aged states) and a high propensity to
aggregate. The tight packing of these massive aggregates
was revealed by TEM and AFM. As compared with WT,
the substitution of a polar negatively charged residue (gluta-
mic acid) by a nonpolar neutral amino acid (valine) led to irre-
versible aggregation even at low concentration (Fig. 1) and
increased cell toxicity (Fig. 6 b), but a similar b-sheet
secondary structure of the aggregates (Fig. 2). On the other
hand, substituting the glutamic acid by the shortest possible
side chain (glycine in E22G) reduced the b-sheet propensity,
as observed by FTIR. This variant yielded a lower amount of
amyloid aggregates, and they showed a different morphology
and stacking of the aggregates compared to the native
sequence and E22V. Thus, the E22G variant formed very
rigid and rod-like amyloid structures in contrast to the
more-flexible and intertwisted fibrillar assemblies for WT
and the E22V variant. The aged E22G sample was more cyto-
toxic than the WT. Even the GG variant was cytotoxic,FIGURE 6 Amyloid quantification and effect on cell
viability of the aged Ab12–28 peptide samples. (a) Congo
red binding assay; 3 mM Congo red absorbance was moni-
tored in the presence of a 40 mM aliquot of the aged peptide
samples (1 mM initial concentration). The average of at
least three independent experiments is plotted and the stan-
dard deviation is shown by error bars. (b) MTT assay to
assess cell viability. Human SH-SY5Y neuroblastoma cells
were incubated overnight in the presence of 0.01 mM
of fresh (light gray bars) or aged (gray bars) peptide in
10 mM phosphate buffer at pH 7.25. Three replicates for
at least two independent experiments were measured. The
cell viability values were normalized for the values
obtained for cells treated with buffer alone.
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Secondary structure* Thermal transition Amyloid / fibrillization Spin label incorporation Effect on cell viability
Fresh sample Aged sample Fresh sample Aged sample Aged sample Fresh sample Aged sample
WT r.c. / ppII b Reversible þþþy/þz Intermediate No No
GG r.c. / ppII r.c. Reversible þ/ None No Yes
E22G r.c. / ppII h / b Reversible þþ/þ Intermediate No Yes
E22V b b Irreversible þþþ/þ High No Yes
Method CD FTIR CD Congo red / TEM and AFM SDSL-EPR / TEM MTT assay
*Statistical sampling of a broad range of f and j angles (r.c.); polyproline II helix (ppII); b-sheet (b); helix (h).
yThe amount of amyloid content detected in the Congo red experiments is translated into a relative scale (þ for small andþþþ for maximal amyloid content).
zThe presence (þ) or absence () of fibrils is derived from the TEM and AFM experiments.although it produced only a small number of round-shaped
aggregates and had no preference for a particular type of
ordered secondary structure. Likely, the flexibility introduced
by the two glycines prevented the adoption of a particular
secondary structure and an ordered arrangement ofmonomers
in the oligomers.
The results show that position 22 (Table 1) is crucial for the
aggregation profile of the Ab fragments. Valine is capable of
establishing strong van der Waals interactions, probably
packing the aggregates by extending the length of the central
hydrophobic core by at least one residue (17–22). On the other
hand, the glutamic acid inWTmakes strong polar interactions
(5). E22V substitutes a strong polar interaction, such as a salt
bridge or hydrogen bond, by a strong hydrophobic interac-
tion, resulting in a tighter packing of the thick fibrillar bundles
detected by TEM and AFM. Gly22 in E22G has no possibility
of interaction, which likely decreases the chances of intermo-
lecular packing, but it does add more flexibility, which then
promotes a mixture of secondary structures.
Peptides with b-sheet structure in the aged aggregated state
formed amyloid fibrils, as revealed byCongo red assay, TEM,
and AFM. However, the correlation is not quantitative.
According to previous studies, some of the toxic aggregates
possess a high percentage of b-sheet structure. However,
other secondary structures may also be toxic, as found in
disordered or a-helical toxic intermediates (4). In this study,
examples of this are the E22G and the GG variants. The
aged state of these low-b-sheet content (if any, for GG) vari-
ants affected the viability of human SH-SY5Y neuroblastoma
cells, whereas the aged native sequence did not show any
effect. This argues for a relatively nontoxic glutamic acid
(WT) and a toxic glycine (E22G) at position 22 in this shorter
fragment. In both glycine variants, less amyloid aggregates
correlated with higher cytotoxicity as compared with theWT.
The process of aggregation of Ab peptide monomers into
different kinds of neurotoxic and nontoxic aggregates is
very complex (30). As described in a recent study (12), vari-
ants at position 22 and 23 destabilize the folding nucleus of
Ab peptide. The data argue for a rearrangement of the mono-
mer folding core in subsequent aggregation. The Arctic E22G
variant leads to higher oligomerization propensity and to
a different aggregation profile, mostly because of the elimina-
tion of electrostatic interactions (change in the starting point
Biophysical Journal 97(1) 277–285of the aggregation process) (5). Molecular-dynamics simula-
tions have suggested that variants involving residue 22 are not
expected to affect the structure of the folding core of Ab
peptide, but rather affect long-range interactions outside the
21–30 sequence (13). Our results provide evidence that
substitutions at position 22 of Ab lead to drastic local effects.
Some of these substitutions affect folding of the monomeric
Ab12–28, as indicated by theb-sheet structure ofmostlymono-
meric E22V and less ppII contributions for E22G as compared
with WT. This in turn leads to different aggregation profiles
as indicated by differences in secondary structure, fibril struc-
ture, spin-label incorporation, and Congo red staining. The
TEM and AFM images describe somewhat different aspects
of the fibril structures, but on thewhole the results they present
for the different variants (e.g., the absence of fibrillar aggre-
gates for the F19G,F20G (GG) variant and the dense fibrils
for the E22V variant) are in agreement.
The different aggregation profiles for Ab variants detected
here call for extra caution when comparing aggregation
processes associated with AD and FAD. Since the structures
and concentrations of the various oligomeric and aggregated
species are different, the neurotoxic mechanisms may also
vary between AD and FAD. Knowledge about the structural
properties of the different peptide variants involved in FAD
is essential for understanding these diseases. As shown here,
a single substitution in Ab can change the structures and
concentrations of the various oligomeric and aggregated
species. We conclude that this aggregation profile is in
general expected to be different for FAD and AD. As a conse-
quence, in vivo modulating factors are also expected to
differ. This could result in a higher or lower accumulation
of potentially neurotoxic species, such as oligomeric forms
of the peptide, or even in different neurotoxic mechanisms.
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